Clinical Trial Detail

NCT ID NCT02625961
Title Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

bladder urothelial carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.